Lipid C2 is an ionizable cationic lipid employed in the development of lipid nanoparticles (LNPs) for in vivo mRNA delivery. In mice, LNPs containing lipid C2 and an mRNA reporter selectively accumulate in the liver and spleen, avoiding significant distribution to the heart, lungs, or kidneys. In a CT26 murine EBV-infected colon cancer model, LNPs with lipid C2 and mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), combined with an anti-PD-1 antibody, effectively reduce tumor volume, reverse T cell exhaustion, increase CD3+CD8+ central and effector memory T cells, and lower the proportion of CD3+ T cells expressing Pd-1 in the spleen.
Usually ships within 24 hours.